Abstract
Broad-spectrum reactivator is an oxime which is able to reactivate acetylcholinesterase (AChE) inhibited by many kinds of organophosphate inhibitors of AChE, mainly nerve agents. There are many AChE reactivators (oximes) as suitable candidates for the broad-spectrum reactivator. Among them, oxime HI-6 is considered as number one, and due to its properties, it is recommended by many armies to be introduced as universal antidotal mean. In this study, we wanted to summarize that the designation “broad spectrum” is prerogative. For this purpose, in vivo evaluation of therapeutical dose of HI-6 (39.0 mg/kg) was performed. Soman, cyclosarin and tabun were used as the typical members of nerve agent family. According to the obtained results, oxime HI-6 did not sufficiently reactivate tabun-inhibited AChE. Brain AChE was also only partially protected. Based on these results, it seems that HI-6 in therapeutical dose has effect only in peripheral compartment.
Keywords: HI-6, Tabun, Cyclosarin, Soman, Broad-spectrum, Oxime
Letters in Drug Design & Discovery
Title: Potency of HI-6 to Reactivate Cyclosarin, Soman and Tabun Inhibited Acetylcholinesterase – In Vivo Study
Volume: 7 Issue: 7
Author(s): Jana Zdarova Karasova, Jiri Kassa, Miroslav Pohanka, Kamil Musilek and Kamil Kuca
Affiliation:
Keywords: HI-6, Tabun, Cyclosarin, Soman, Broad-spectrum, Oxime
Abstract: Broad-spectrum reactivator is an oxime which is able to reactivate acetylcholinesterase (AChE) inhibited by many kinds of organophosphate inhibitors of AChE, mainly nerve agents. There are many AChE reactivators (oximes) as suitable candidates for the broad-spectrum reactivator. Among them, oxime HI-6 is considered as number one, and due to its properties, it is recommended by many armies to be introduced as universal antidotal mean. In this study, we wanted to summarize that the designation “broad spectrum” is prerogative. For this purpose, in vivo evaluation of therapeutical dose of HI-6 (39.0 mg/kg) was performed. Soman, cyclosarin and tabun were used as the typical members of nerve agent family. According to the obtained results, oxime HI-6 did not sufficiently reactivate tabun-inhibited AChE. Brain AChE was also only partially protected. Based on these results, it seems that HI-6 in therapeutical dose has effect only in peripheral compartment.
Export Options
About this article
Cite this article as:
Zdarova Karasova Jana, Kassa Jiri, Pohanka Miroslav, Musilek Kamil and Kuca Kamil, Potency of HI-6 to Reactivate Cyclosarin, Soman and Tabun Inhibited Acetylcholinesterase – In Vivo Study, Letters in Drug Design & Discovery 2010; 7 (7) . https://dx.doi.org/10.2174/157018010791526269
DOI https://dx.doi.org/10.2174/157018010791526269 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Amyloidogenesis Investigated by Small Angle Scattering
Current Pharmaceutical Design Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Psychiatry Reviews Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Current Pharmaceutical Design Transitional Age Youth with Serious Mental Illness: High Acuity Patients Requiring Developmentally Informed Care in the Inpatient Hospital Setting
Adolescent Psychiatry Elevated Plasma Levels of α -1-Anti-Chymotrypsin in Age-Related Cognitive Decline and Alzheimers Disease: A Potential Therapeutic Target
Current Pharmaceutical Design Cellular Mechanisms of Striatum-Dependent Behavioral Plasticity and Drug Addiction
Current Molecular Medicine Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Muscarinic Acetylcholine Receptors
Current Pharmaceutical Design Pyrimidine Derivatives as Potential Agents Acting on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Reviews on Recent Clinical Trials Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer`s Disease
Current Neurovascular Research Relevance of Excitable Media Theory and Retinal Spreading Depression Experiments in Preclinical Pharmacological Research
Current Neuropharmacology Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art
Current Radiopharmaceuticals N-alkylated Tacrine Derivatives as Potential Agents in Alzheimer’s Disease Therapy
Current Alzheimer Research Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Oxidative Stress in Alzheimer Patients in Different Stages of the Disease
Current Medicinal Chemistry Combination of Electrochemical, Spectrometric and Other Analytical Techniques for High Throughput Screening of Pharmaceutically Active Compounds
Combinatorial Chemistry & High Throughput Screening The “Tilted Peptide Theory” Links Membrane Insertion Properties and Fusogenicity of Viral Fusion Peptides
Protein & Peptide Letters